Masimo (NASDAQ:MASI) Sets New 12-Month High – Time to Buy?

Masimo Co. (NASDAQ:MASI) hit a new 52-week high during trading on Tuesday . The company traded as high as $194.88 and last traded at $190.63, with a volume of 896907 shares changing hands. The stock had previously closed at $188.77.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on MASI shares. Wells Fargo & Company boosted their price target on shares of Masimo from $193.00 to $205.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 26th. Stifel Nicolaus restated a “buy” rating and issued a $190.00 price target (up from $170.00) on shares of Masimo in a research report on Friday, November 22nd. Needham & Company LLC reaffirmed a “hold” rating on shares of Masimo in a report on Wednesday, February 26th. Piper Sandler boosted their price objective on Masimo from $210.00 to $215.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 26th. Finally, Raymond James raised their target price on Masimo from $170.00 to $194.00 and gave the stock an “outperform” rating in a research note on Friday, December 27th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $194.80.

Masimo Stock Up 1.0 %

The stock has a market capitalization of $10.28 billion, a price-to-earnings ratio of 131.47 and a beta of 1.02. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.01 and a quick ratio of 1.11. The business has a fifty day moving average of $174.13 and a 200 day moving average of $154.63.

Masimo (NASDAQ:MASI) last announced its quarterly earnings results on Tuesday, February 25th. The medical equipment provider reported $1.80 EPS for the quarter, beating the consensus estimate of $1.42 by $0.38. The business had revenue of $600.70 million for the quarter, compared to analyst estimates of $593.35 million. Masimo had a return on equity of 14.98% and a net margin of 3.85%. As a group, equities analysts predict that Masimo Co. will post 4.1 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. Jones Financial Companies Lllp acquired a new position in shares of Masimo in the 4th quarter worth approximately $27,000. UMB Bank n.a. increased its holdings in Masimo by 180.9% in the 4th quarter. UMB Bank n.a. now owns 191 shares of the medical equipment provider’s stock valued at $32,000 after purchasing an additional 123 shares during the last quarter. Blue Trust Inc. raised its position in Masimo by 56.3% in the fourth quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider’s stock valued at $33,000 after purchasing an additional 71 shares during the period. Trust Co. of Vermont acquired a new position in Masimo during the fourth quarter worth $33,000. Finally, EverSource Wealth Advisors LLC boosted its position in shares of Masimo by 40.0% during the fourth quarter. EverSource Wealth Advisors LLC now owns 224 shares of the medical equipment provider’s stock worth $37,000 after buying an additional 64 shares during the period. Hedge funds and other institutional investors own 85.96% of the company’s stock.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.